Liraglutide Evaluation in the CDAHFD Model
We would like to share with you our latest data obtained using the CDAHFD (Choline-Deficient, High-Fat Diet) mouse model, which rapidly reproduces key features of MASH, including steatosis, inflammation, and fibrosis.
In this study, we evaluated the GLP-1 receptor agonist Liraglutide, and observed a clear anti-fibrotic effect in this model.
Overview of the CDAHFD Model
- Induced by a diet deficient in choline, enriched with 60% fat, and supplemented with 0.1% methionine
- Rapid reproduction of MASH-like pathology—including steatosis, hepatic inflammation, and fibrosis—within several weeks
[In-House Data] Liraglutide Suppresses Liver Fibrosis
In our in vivo study using the CDAHFD model, Liraglutide treatment resulted in significant reduction in fibrosis scores compared to the control group.
If you would like to review detailed histological images or supporting data from this study, please feel free to contact us.
This model offers a valuable tool for early-stage compound screening and the study of fibrosis mechanisms.
We would be delighted to support your research.